Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis
Chandra, Abhishek , Wang, Luqiang, Young, Tiffany, Zhong, Leilei , Tseng, Wei‐Ju , Levine, Michael A. , Cengel, Keith A. , Pignolo, Robert J. , Qin, Ling , Liu, X. Sherry , Zhang, Yejia , Levine, M A , Chandra, Abhishek

Mayo Clinic

The FASEB Journal | August 31, 2017 | Volume: 32 | Issue: 1 | Pages: 52-62

10.1096/fj.201700375r | PMID 28860152 Get It

Bone atrophy and its related fragility fractures are frequent, late side effects of radiotherapy in cancer survivors and have a detrimental impact on their quality of life. In another study, we showed that parathyroid hormone 1‐34 and anti‐sclerostin antibody attenuates radiation‐induced bone damage by accelerating DNA repair in osteoblasts. DNA damage responses are partially regulated by the ubiquitin proteasome pathway. In the current study, we examined whether proteasome inhibitors have similar bone‐protective effects against radiation damage. MG132 treatment greatly reduced radiation‐induced apoptosis in cultured osteoblastic cells. This survival effect was owing to accelerated DNA repair as revealed by γH2AX foci and comet assays and to the up‐regulation of Ku70 and DNA‐dependent protein kinase, catalytic subunit, essential DNA repair proteins in the nonhomologous end‐ joining pathway. Administration of bortezomib (Bzb) reversed the loss of trabecular bone structure and strength in mice at 4 wk after focal radiation. Histomorphometry revealed that Bzb significantly increased the number of osteoblasts and activity in the irradiated area and suppressed the number and activity of osteoclasts, regardless of irradiation. Two weeks of Bzb treatment accelerated DNA repair in bone‐lining osteoblasts and thus promoted their survival. Meanwhile, it also inhibited bone marrow adiposity. Taken together, we demonstrate a novel role of proteasome inhibitors in treating radiation‐induced osteoporosis.—Chandra, A., Wang, L., Young, T., Zhong, L., Tseng, W.‐J., Levine, M. A., Cengel, K., Liu, X. S., Zhang, Y., Pignolo, R. J., Qin, L. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis. FASEB J. 32, 52‐62 (2018). www.fasebj.org
Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis
Kulik, Laura , Zaiem, Feras, Almasri, Jehad , Murad, M. Hassan , Mohammed, Khaled , Murad, M Hassan , Heimbach, Julie K. , Prokop, Larry J. , Wang, Zhen

Mayo Clinic

Hepatology | August 31, 2017 | Volume: 67 | Issue: 1 | Pages: 381-400

10.1002/hep.29485 | PMID 28859222 Get It

Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist. We conducted a comprehensive search of multiple databases from 1996 to April 25, 2016, for studies that enrolled adults with cirrhosis awaiting LT and treated with bridging or down‐staging therapies before LT. Therapies included transcatheter arterial chemoembolization, transarterial radioembolization, ablation, and radiotherapy. We included both comparative and noncomparative studies. There were no randomized controlled trials identified. For adults with T1 HCC and waiting for LT, there were only two nonrandomized comparative studies, both with a high risk of bias, which reported the outcome of interest. In one series, the rate of dropout from all causes at 6 months in T1 HCC patients who underwent LRT was 5.3%, while in the other series of T1 HCC patients who did not receive LRT, the dropout rate at median follow‐up of 2.4 years and the progression rate to T2 HCC were 30% and 88%, respectively. For adults with T2 HCC awaiting LT, transplant with any bridging therapy showed a nonsignificant reduction in the risk of waitlist dropout due to progression (relative risk [RR], 0.32; 95% confidence interval [CI], 0.06‐1.85; I 2 = 0%) and of waitlist dropout from all causes (RR, 0.38; 95% CI, 0.060‐2.370; I 2 = 85.7%) compared to no therapy based on three comparative studies. The quality of evidence is very low due to high risk of bias, imprecision, and inconsistency. There were five comparative studies which reported on posttransplant survival rates and 10 comparative studies which reported on posttransplant recurrence, and there was no significant difference seen in either of these endpoints. For adults initially with stage T3 HCC who received LRT, there were three studies reporting on transplant with any down‐staging therapy versus no downstaging, and this showed a significant increase in 1‐year (two studies, RR, 1.11; 95% CI, 1.01‐1.23) and 5‐year (1 study, RR, 1.17; 95% CI, 1.03‐1.32) post‐LT survival rates for patients who received LRT. The quality of evidence is very low due to serious risk of bias and imprecision. Conclusion: In patients with HCC listed for LT, the use of LRT is associated with a nonsignificant trend toward improved waitlist and posttransplant outcomes, though there is a high risk of selection bias in the available evidence. (H epatology 2018;67:381‐400).
Spatial Differences in Cellular and Molecular Responses as a Function of the Material Used in Conduit‐Mediated Repair and Autograft Treatment of Peripheral Nerve Injuries
Daly, William T. , Niemier, Ryan, Dillon, Simon T. , Mirsky, Rhona, Jessen, Kristján R. , Windebank, Anthony J. , Pandit, Abhay , Wang, Huan

Mayo Clinic

Advanced Functional Materials | August 31, 2017 | Volume: 28 | Issue: 12 | Pages: No page available

10.1002/adfm.201702170 Get It

AbstractThe treatment of peripheral nerve injuries remains a major problem worldwide despite the availability of a number of Food and Drug Administration (FDA) approved devices which fail to match the efficacy of autografts. Different strategies are used to improve regeneration and functional recovery using biomaterial nerve conduits. However, there is little investigation of the transcriptomic and proteomic changes which occur as a result of these interventions, particularly regarding transection injuries. This study explores differences between autograft‐mediated repair and conduit‐material‐mediated repair of peripheral nerve injuries to understand fundamental differences in their repair mechanisms at the proteomics level at the proximal, middle, and distal components in the early stages of repair. Pathway analysis demonstrates that each material selectively activates different regenerative pathways and alters different biological functions spatially throughout the biomaterial conduits. The analysis highlights some of the deficiencies in conduit‐mediated repair in comparison to autograft (e.g., recycling of myelin and cholesterol, reduction in reactive oxygen species, and higher expression of regenerative proteins). These findings thus suggest that by supplementing the expression of these proteins on the biomaterial of choice, this study can potentially attain regeneration equivalent to autograft. This approach paves the way for incorporating future biomaterial‐specific functionalities in nerve guidance conduits.
Dependency and AMR Embeddings for Drug-Drug Interaction Extraction from Biomedical Literature
Wang, Yanshan , Wang, Liwei , Shen, Feichen , Liu, Fei , Liu, Sijia , Rastegar-Mojarad, Majid , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology,and Health Informatics | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: 36-43

10.1145/3107411.3107426 Get It

Author response: NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Zhu, Yun , Gao, Xuyuan , Tin, Vicky Pui‐Chi, Wong, Maria Pik , Liu, Jing , Wang, Siqi , Qin, Jing , Wang, Junwen , Wong, Maria Pik

Mayo Clinic

No container title available | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.26733.032 Get It

Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis
Sonbol, Mohamad Bassam , Firwana, Belal , Wang, Zhen , Almader‐Douglas, Diana , Makhoul, Issam , Ramanathan, Ramesh K., Ahn, Daniel H. , Bekaii‐Saab, Tanios , Ahn, Daniel H , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Borad, Mitesh J.

Mayo Clinic

Cancer | August 17, 2017 | Volume: 123 | Issue: 23 | Pages: 4680-4686

10.1002/cncr.30927 | PMID 28817187 Get It

BACKGROUNDThere are limited therapeutic options for treatment‐refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine‐based regimens. The authors performed a meta‐analysis to determine the effectiveness of adding oxaliplatin (OX) or various irinotecan formulations to a fluoropyrimidine (FP) after first‐line treatment progression in patients with PDAC.METHODSDifferent databases, including PubMed, EMBASE, and Cochrane, were searched to identify randomized controlled trials comparing FP monotherapy versus FP combination therapy that included either oxaliplatin (FPOX) or various irinotecan formulations (FPIRI) in patients with PDAC who progressed after first‐line treatment. Secondary analyses were planned to assess the effectiveness of FPOX and FPIRI compared with FP. Outcomes of interest included overall survival (OS) and progression‐free survival (PFS).RESULTSFive studies with 895 patients were identified. Patients randomized to receive FPIRI/FPOX had a significantly improved PFS and a trend toward improved OS compared with those who received FP monotherapy. When comparing FPIRI with FP, there was an improvement in both PFS (hazard ratio, 0.64; 95% confidence interval, 0.47‐0.87; P = .005) and OS (hazard ratio, 0.70; 95% confidence interval, 0.55‐0.89; P = .004) in patients who received the combination. Conversely, FPOX produced only a modest improvement in PFS with no improvement in OS.CONCLUSIONSCombination chemotherapy with OX or various IRI formulations appears to improve PFS compared with single‐agent FP. FPIRI, but not FPOX, appears to confer an OS advantage. The combination of FP with irinotecan formulations appears to be the appropriate next line of treatment upon progression after gemcitabine‐based chemotherapy regimens. Cancer 2017;123:4680‐4686. © 2017 American Cancer Society.
IRF4 Modulates CD8+ T Cell Sensitivity to IL-2 Family Cytokines
Huang, Su, Shen, Yingjia, Pham, Duy , Jiang, Li , Wang, Zheng , Kaplan, Mark H. , Zhang, Guangjun , Kaplan, Mark H , Sun, Jie

Mayo Clinic

ImmunoHorizons | August 15, 2017 | Volume: 1 | Issue: 6 | Pages: 92-100

10.4049/immunohorizons.1700020 | PMID 29564420 Get It

Abstract IFN regulatory factor 4 (IRF4) is a key transcription factor that promotes effector CD8+ T cell differentiation and expansion. The roles of IRF4 in regulating the CD8+ T cell response to cytokines have not been explored. In this article, we show that IL-2 and IL-15 signaling and STAT5 activation regulate IRF4 expression in CD8+ T cells. Gene-expression profile analysis has also revealed that IRF4 is required for expression of the receptors of IL-2 family cytokines CD122 and CD127. We found that IRF4 binds directly to CD122 and CD127 gene loci, indicating that it may directly promote CD122 and CD127 gene transcription. As a consequence, IRF4-deficient CD8+ T cells show diminished sensitivity to IL-2, IL-15, and IL-7 treatment in vitro. Furthermore, we found that IRF4-deficient CD8+ T cells had lower expression of CD122 and CD127 in vivo during influenza virus infection. These data suggest that IRF4 regulates the sensitivity of CD8+ T cells to IL-2 family cytokines, which correlates with the diminished effector and memory CD8+ T cell responses in IRF4-deficient CD8+ T cells.
Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients
Wang, Jin , Glaser, Kevin J. , Zhang, Tianhui , Shan, Qungang , He, Bingjun , Yin, Meng , Dzyubak, Bogdan , Kugel, Jennifer L., Kruse, Scott A., Grimm, Roger C., Venkatesh, Sudhakar K. , Dzyubak, Bogdan , Venkatesh, Sudhakar K , Yin, Meng , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 12, 2017 | Volume: 47 | Issue: 4 | Pages: 976-987

10.1002/jmri.25818 | PMID 28801939 Get It

PurposeTo assess the success rate, image quality, and the ability to stage liver fibrosis of a standard 2D gradient‐recalled echo (GRE) and four different spin‐echo (SE) magnetic resonance elastography (MRE) sequences in patients with different liver iron concentrations.Materials and MethodsA total of 332 patients who underwent 3T MRE examinations that included liver fat and iron quantification were enrolled, including 136 patients with all five MRE techniques. Thirty‐four patients had biopsy results for fibrosis staging. The liver stiffness, region of interest area, image quality, and success rate of the five sequences were compared in 115/136 patients. The area under the receiver operating characteristic curves (AUCs) and the accuracies for diagnosing early‐stage fibrosis and advanced fibrosis were compared. The effect of BMI (body mass index), the R2* relaxation time, and fat fraction on the image quality and liver stiffness measurements were analyzed.ResultsThe success rates were significantly higher in the four SE sequences (99.1–100%) compared with GRE MRE (85.3%) (all P < 0.001). There were significant differences of the mean ROI area between every pair of sequences (all P < 0.0001). There were no significant differences in the AUC of the five MRE sequences for discriminating advanced fibrosis (10 P‐values ranging from 0.2410–0.9171). R2* had a significant effect on the success rate and image quality for the noniron 2D echo‐planar imaging (EPI), 3D EPI and 2D GRE (all P < 0.001) sequences. BMI had a significant effect on the iron 2D EPI (P = 0.0230) and iron 2D SE (P = 0.0040) sequences.ConclusionAll five techniques showed good diagnostic performance in staging liver fibrosis. The SE MRE sequences had higher success rates and better image quality than GRE MRE in 3T clinical hepatic imaging.Level of Evidence: 3Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2018;47:976–987.
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations
Durham, Benjamin H. , Getta, Bartlomiej , Won, Helen , Scott, Sasinya N., Chung, Young Rock , Chung, Stephen S. , Hüllein, Jennifer , Walther, Tatjana, Wang, Lu , Oakes, Christopher C. , Tibes, Raoul , Haferlach, Torsten , Taylor, Barry S. , Tallman, Martin S. , Park, Jae H. , Bogenberger, James M. , Abdel-Wahab, Omar , Dietrich, Sascha , Taylor, Justin , Kim, Eun Hee , Lu, Sydney X. , Berger, Michael , Zenz, Thorsten , Abdel‐Wahab, Omar , Durham, Benjamin

Mayo Clinic

Blood | August 11, 2017 | Volume: 130 | Issue: 14 | Pages: 1644-1648

10.1182/blood-2017-01-765107 | PMID 28801450 Get It

Key Points KMT2C mutations occur in 15% and 25% of patients with cHCL and vHCL, respectively, along with CCND3 and U2AF1 mutations each in 13% of vHCLs. NF1, NF2, N/KRAS, and IRS1 alterations contribute to clinical resistance to vemurafenib treatment in patients with cHCL.
Author response: Unexpected sequences and structures of mtDNA required for efficient transcription from the first heavy-strand promoter
Uchida, Akira , Murugesapillai, Divakaran , Wang, Yao , Lodeiro, María F. , Prabhakar, Shaan, Oliver, Guinevere V , Arnold, Jamie J. , Maher, L. James, Cameron, Craig E. , Kastner, Markus , Williams, Mark C.

Mayo Clinic

No container title available | August 10, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.27283.032 Get It